Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
Alzheimer’s disease (AD) is a severe neurodegenerative brain disorder. The determination of beta-amyloid (Aβ)-40, –42, total tau, and phospho-tau-181 (pTau181) in cerebrospinal fluid (CSF) using Lumipulse technology has been established as biomarkers for AD in recent years. As CSF collection is an i...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2022-09-01
|
| Edice: | Frontiers in Aging Neuroscience |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.1014305/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|